Kali Therapeutics has entered a licensing deal with Sanofi, granting exclusive global rights to KT501, a tri-specific T-cell engager aimed at treating B cell-mediated autoimmune diseases. Sanofi will pay $180 million upfront and could pay up to $1.05 billion in milestones plus royalties. KT501 is currently in early human trials for Rheumatoid Arthritis, designed to deplete B cells effectively while minimizing side effects. This collaboration leverages Kali's innovative protein engineering to potentially offer safer, more effective autoimmune treatments.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
